MOSCOW (Reuters) – Russian Direct Investment Fund (RDIF) and pharmaceutical company Dr. Reddy's Laboratories Ltd has agreed to conduct clinical trials and ship the Sputnik V vaccine to India, RDIF said on Wednesday.
After regulatory approval, for which Dr. Reddy's will begin Phase III clinical trials of the vaccine in India with 100 million doses shipped to the country. Deliveries could begin in late 2020 after the vaccine is registered in India.
“India is among the countries most severely affected by the coronavirus, and we believe that our platform based on two human adenovirus vectors will provide India with a safe and scientifically proven tool to fight the coronavirus,” said Kirill Dmitriev, head of RDIF.
In August, the Sputnik V vaccine produced by the N.N. N.F. Gamaleya received a registration certificate from the Russian Ministry of Health, becoming the first registered coronavirus vaccine in the world.
(Polina Ivanova, Anastasia Teterevleva; editor Anton Kolodyazhny)